aim
viral
pneumonia
seriou
complic
immunocompromis
children
aetiolog
difficult
identifi
owe
limit
convent
microbiolog
test
aim
studi
determin
whether
polymeras
chain
reaction
pcr
assay
respiratori
virus
increas
diagnost
yield
bronchoalveolar
lavag
bal
immunocompromis
children
method
bal
sampl
obtain
immunocompromis
children
hospit
pneumonia
process
respiratori
virus
viral
cultur
rapid
antigen
test
pcr
cmv
adenoviru
influenza
parainfluenza
herpesviru
rsv
hmpv
result
studi
group
includ
patient
mean
age
ae
year
episod
clinic
pneumonia
bal
sampl
forti
viral
pathogen
identifi
episod
pcr
increas
diagnost
rate
fourfold
identifi
pcr
alon
p
viral
cultur
rapid
antigen
test
use
gold
standard
pcr
found
high
sensit
assess
specif
pcr
result
prompt
initi
specif
antivir
therapi
avoid
unnecessari
antibiot
treatment
episod
conclus
pcrbase
diagnosi
bal
may
increas
rate
pathogen
detect
immunocompromis
children
decreas
time
diagnosi
spare
patient
unnecessari
antimicrobi
treatment
introduct
viral
pneumonia
seriou
infecti
complic
immunocompromis
children
adult
associ
high
rate
morbid
includ
respiratori
multiorgan
failur
increas
rate
hospit
need
intens
care
mortal
rate
diagnosi
often
difficult
clinic
radiolog
find
lack
sensit
specif
viral
cultur
timeconsum
low
sensit
direct
antigen
assay
lack
sensit
although
allow
rapid
diagnosi
unavail
wide
rang
viral
pathogen
recent
year
molecular
techniqu
gene
amplif
appli
rapid
sensit
detect
infecti
agent
polymeras
chain
reaction
pcr
assay
viral
respiratori
pathogen
shown
high
sensit
specif
studi
report
twoto
threefold
increas
diagnost
yield
pcr
ad
standard
microbiolog
investig
differ
studi
case
virusposit
pcr
also
posit
viral
cultur
posit
rate
rapid
antigen
test
viral
pcrposit
case
children
sever
studi
valid
use
pcr
detect
viral
pathogen
includ
influenza
viru
parainfluenza
viru
adenoviru
respiratori
syncyti
viru
abbrevi
bal
bronchoalveolar
lavag
bmt
bone
marrow
transplant
pcr
polymeras
chain
reaction
rsv
respiratori
syncyti
viru
immunocompromis
children
pneumonia
viral
pcr
assay
compar
standard
microbiolog
assay
viral
cultur
rapid
antigen
test
bronchoalveolar
lavag
increas
diagnosi
yield
fourfold
viral
cultur
rapid
antigen
test
use
gold
standard
pcr
found
high
sensit
specif
pcr
assay
also
support
discontinu
unnecessari
antibiot
treatment
episod
rsv
human
metapneumoviru
hmpv
rhinoviru
coronaviru
herpesviru
howev
data
immunocompromis
children
particular
still
spars
especi
pcr
test
bronchoalveolar
lavag
bal
fluid
aim
present
studi
determin
whether
pcr
test
respiratori
virus
add
diagnost
yield
bal
immunocompromis
children
pneumonia
retrospect
studi
conduct
paediatr
intens
care
unit
schneider
children
medic
center
israel
tertiari
care
universityaffili
paediatr
facil
infant
children
primari
secondari
immunodefici
hospit
pneumonia
januari
june
need
bal
includ
studi
episod
bal
sampl
analys
use
standard
microbiolog
test
cultur
rapid
antigen
test
pcrbase
assay
includ
analysi
studi
approv
institut
review
board
rabin
medic
center
waiv
need
inform
consent
patient
medic
file
review
follow
data
age
sex
underli
diseas
predispos
factor
durat
hospit
intens
care
unit
prior
viral
infect
presenc
fever
respiratori
distress
laboratori
data
blood
cell
count
chemistri
result
radiolog
find
antimicrobi
therapi
bal
fluid
analysi
result
bal
fluid
analysi
clinic
decis
base
bal
test
result
clinic
outcom
episod
present
studi
conduct
simultan
studi
fungal
pathogen
use
pcr
standard
test
fungal
cultur
calcofluor
stain
immunofluoresc
stain
pneumocysti
jirovecii
cohort
bal
procedur
bal
perform
bronchoscopi
suit
within
paediatr
intens
care
unit
patient
prepar
procedur
inhal
adrenalin
lidocain
sedat
midazolam
atropin
propofol
fiberopt
bronchoscop
wedg
subsegment
bronchu
affect
lobelob
ml
aliquot
steril
normal
salin
solut
aspir
bal
fluid
transfer
examin
sampl
bal
fluid
test
presenc
adenoviru
cytomegaloviru
cmv
parainfluenza
viru
herpesviru
rsv
adenoviru
influenza
viru
realtim
pcr
perform
use
taqman
probe
detect
system
adenoviru
cmv
herpesviru
realtim
revers
transcriptas
pcr
assay
perform
influenza
viru
rsv
hmpv
revers
transcriptas
pcr
use
parainfluenza
viru
viral
cultur
rapid
antigen
test
rsv
perform
microbiolog
depart
rabin
medic
center
pcr
assay
perform
central
virolog
laboratori
chaim
sheba
medic
center
adenoviru
detect
amplif
conserv
region
hexon
gene
detect
infect
junction
glycoprotein
gj
amplifi
detect
amplif
glycoprotein
g
influenza
viru
specif
primer
select
amplifi
part
influenza
viru
mprotein
gene
influenza
b
viru
specif
primer
design
amplifi
part
ha
gene
detect
rsv
b
n
gene
rsv
chosen
target
hmpv
l
gene
select
parainfluenza
virus
detect
use
multiplex
rtpcr
assay
detect
differenti
viral
genom
dna
extract
bal
fluid
qiaamp
dna
blood
mini
kit
qiagen
gmbh
hilden
germani
viral
genom
rna
extract
high
pure
viral
rna
kit
roch
diagnost
gmbh
mannheim
germani
test
cmv
dna
extract
bal
fluid
use
magnapur
lc
total
nucleic
acid
isol
kit
roch
diagnost
accord
manufactur
instruct
abi
realtim
pcr
system
appli
biosystem
foster
citi
ca
usa
use
one
primer
set
design
highli
conserv
region
glycoprotein
b
major
envelop
glycoprotein
cmv
gene
second
set
design
highli
conserv
immedi
earli
region
immunosuppress
defin
current
treatment
chemotherapi
immunosuppress
therapi
bone
marrow
transplant
known
primari
immun
defici
clinic
pneumonia
diagnos
least
two
follow
four
criteria
met
fever
new
pulmonari
infiltr
worsen
pulmonari
infiltr
dyspnoea
indic
bal
clinic
pneumonia
respond
empir
therapi
within
h
decis
add
pcr
test
base
patient
histori
find
physic
examin
histori
viral
infect
radiolog
find
presenc
specif
risk
factor
clinic
improv
defin
resolut
least
two
three
diagnost
criteria
fever
respiratori
symptom
pulmonari
infiltr
chest
film
within
week
bal
diagnost
rate
standard
microbiolog
method
viral
cultur
rapid
antigen
test
pcr
calcul
percentag
viral
pathogen
identifi
method
differ
diagnost
rate
standard
method
pcr
analys
chisquar
test
cultur
rapid
antigen
test
serv
refer
gold
standard
calcul
pcr
sensit
specif
viral
pathogen
posit
neg
predict
valu
calcul
low
number
posit
find
pathogen
episod
respiratori
ill
divid
two
group
diagnos
standard
method
posit
neg
pcr
result
diagnos
pcr
alon
group
compar
percentag
episod
clinic
improv
occur
total
episod
group
percentag
patient
die
hospit
total
number
patient
group
differ
rate
clinic
improv
mortal
two
group
analys
chisquar
test
p
valu
consid
signific
studi
cohort
includ
patient
total
episod
clinic
pneumonia
bal
sampl
patient
characterist
present
tabl
episod
antibiot
treatment
start
prior
bal
suspect
bacteri
pulmonari
infect
episod
antivir
therapi
ribavirin
cidofovir
ganciclovir
also
start
prior
bal
suspect
viral
pulmonari
infect
base
previou
infect
week
month
current
pneumonia
episod
cmv
andor
adenoviru
case
addit
four
episod
patient
receiv
antivir
prophylaxi
acyclovir
time
bal
episod
patient
treat
antifung
therapi
ie
amphotericin
voriconazol
fluconazol
time
bal
examin
sampl
episod
neg
viral
antigen
standard
test
cultur
rapid
antigen
test
pcr
episod
viral
pathogen
identifi
episod
viral
pathogen
identifi
tabl
ten
pathogen
isol
standard
test
viral
cultur
nine
pathogen
rapid
antigen
test
pathogen
rsv
either
neg
posit
result
pcr
assay
pathogen
p
detect
pcr
alon
addit
pcr
bal
evalu
increas
diagnost
yield
fourfold
pathogen
often
detect
adenoviru
episod
follow
cmv
nine
episod
rsv
eight
episod
influenza
viru
four
episod
influenza
b
three
episod
one
episod
parainfluenza
four
episod
herpesviru
two
three
episod
rsv
influenza
posit
episod
occur
winter
earli
spring
month
none
episod
posit
hmpv
viral
cultur
rapid
antigen
test
use
gold
standard
pcr
found
high
sensit
assess
specif
episod
posit
viral
infect
coinfect
pathogen
observ
tabl
bacteri
pathogen
episod
compar
viralneg
episod
viral
pathogen
eight
episod
fungal
pathogen
six
episod
compar
viralneg
episod
episod
find
three
diagnost
method
neg
empir
antivir
therapi
discontinu
withheld
episod
includ
studi
among
episod
viral
pathogen
identifi
antivir
therapi
initi
continu
treatment
case
consist
ganciclovir
cmv
infect
four
episod
foscarnet
cmv
infect
four
episod
adenoviru
infect
one
episod
cidofovir
adenoviru
infect
six
episod
ribavirin
rsv
infect
one
episod
valganciclovir
cmv
infect
one
episod
basi
diagnosi
viral
infect
empir
antibiot
treatment
discontinu
withheld
episod
clinic
improv
note
episod
followup
data
avail
episod
includ
episod
diagnos
pcr
alon
within
subgroup
clinic
improv
observ
episod
compar
episod
diagnos
standard
method
p
nine
patient
die
hospit
bal
perform
inhospit
mortal
includ
patient
episod
diagnos
pcr
alon
inhospit
mortal
rate
pcrbase
diagnosi
group
lower
mortal
rate
standard
methodsdiagnos
group
respect
p
present
studi
bal
sampl
immunocompromis
children
clinic
pneumonia
test
pcr
assay
addit
standard
microbiolog
method
viral
cultur
rapid
antigen
test
compar
standard
test
pcr
high
rate
sensit
assess
specif
addit
pcr
increas
rate
diagnosi
viral
pathogen
test
especi
adenoviru
rsv
influenza
viru
parainfluenza
viru
significantli
increas
fourfold
diagnost
yield
bal
sampl
pathogen
identifi
pcr
alon
vs
pathogen
identifi
standard
method
pcr
assay
also
promot
initi
continu
specif
antivir
therapi
posit
episod
best
knowledg
publish
studi
compar
effect
viral
pcr
standard
microbiolog
method
use
bal
fluid
immunocompromis
children
rate
diagnosi
viral
infect
addit
pcr
consist
previou
find
immunocompromis
patient
gerna
colleagu
found
respiratori
infect
adult
lung
transplant
recipi
posit
pcr
sensit
could
assess
episod
posit
viru
standard
pcr
assay
pcr
sensit
specif
could
assess
convent
assay
parainfluenza
done
accordingli
viral
infect
appear
play
signific
role
immunocompromis
patient
inform
provid
pcr
assay
also
import
prevent
unnecessari
treatment
antivir
treatment
discontinu
withheld
episod
standard
test
pcr
yield
neg
find
antibiot
therapi
discontinu
withheld
episod
viral
pathogen
identifi
noteworthi
bacteri
cultur
bal
may
larg
neg
episod
patient
alreadi
treat
antibiot
time
bal
detect
viral
pathogen
pcr
decreas
likelihood
bacteri
infect
support
avoid
antibiot
therapi
antibiot
therapi
discontinu
day
case
averag
time
occurr
fever
receiv
pcr
result
bal
done
day
antibiot
treatment
start
case
coinfect
viral
pathogen
bacteri
viral
fungal
pathogen
common
studi
two
common
virus
coinfect
rsv
adenoviru
coinfect
report
studi
viral
pcr
assay
especi
children
immunocompromis
patient
rate
possibl
pitfal
reli
pcr
assay
risk
fals
posit
healthi
subject
may
carri
viral
particl
respiratori
secret
mostli
due
previou
infect
viral
pcr
assay
may
sometim
yield
posit
result
even
absenc
respiratori
ill
thavagnanam
colleagu
test
nonbronchoscop
bal
sampl
healthi
asthmat
children
pcr
assay
common
viral
pathogen
rate
posit
result
children
without
respiratori
ill
howev
problem
may
less
relev
immunocompromis
patient
one
studi
adult
lung
transplant
recipi
falseposit
rate
pcr
assay
viral
pathogen
patient
respiratori
symptom
compar
patient
respiratori
tract
infect
bal
sampl
taken
respiratori
ill
evalu
viral
pathogen
pcr
neg
find
suggest
respiratori
virus
caus
latent
infect
present
studi
could
accur
evalu
falseposit
rate
pcr
result
analys
standard
test
known
low
sensit
nevertheless
although
find
statist
signific
patient
treatment
direct
sole
posit
pcr
result
higher
rate
clinic
improv
lower
mortal
could
expect
find
pcr
result
fals
posit
support
assumpt
falseposit
rate
pcr
low
anoth
limit
potenti
risk
bal
bronchoscopi
invas
procedur
carri
sever
risk
especi
immunocompromis
patient
respiratori
diseas
among
bleed
respiratori
failur
studi
bronchoscopi
done
paediatr
intens
care
unit
sedat
gener
anaesthesia
complic
observ
also
case
mortal
day
follow
procedur
howev
benefit
bal
consid
potenti
risk
procedur
everi
patient
limit
studi
retrospect
singlecentr
design
studi
rel
small
number
episod
evalu
heterogen
patient
eg
primari
immunodefici
bone
marrow
transplant
patient
addit
pcr
assay
avail
us
includ
coronaviru
rhinoviru
increasingli
acknowledg
signific
pathogen
patient
respiratori
tract
infect
especi
immunocompromis
patient
possibl
diagnost
yield
would
even
higher
addit
examin
conclus
viral
pcr
assay
increas
diagnost
yield
bal
immunocompromis
children
pneumonia
prompt
initi
specif
antivir
treatment
spare
patient
unnecessari
treatment
